{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T20:27:14Z","timestamp":1782332834935,"version":"3.54.5"},"reference-count":85,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Ther. Deliv."],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.4155\/tde.14.118","type":"journal-article","created":{"date-parts":[[2015,4,8]],"date-time":"2015-04-08T16:30:02Z","timestamp":1428510602000},"page":"283-295","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Subcutaneous Formulation of Tocilizumab for Treatment of Rheumatoid Arthritis"],"prefix":"10.1080","volume":"6","author":[{"given":"Atsushi","family":"Ogata","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Allergy &amp; Rheumatic Diseases, Osaka University Graduate School of Medicine, 2\u20132 Yamada-oka, Suita City, Osaka University, Osaka, 565\u20130871, Japan"},{"name":"Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Allergy &amp; Rheumatic Diseases, Osaka University Graduate School of Medicine, 2\u20132 Yamada-oka, Suita City, Osaka University, Osaka, 565\u20130871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Allergy &amp; Rheumatic Diseases, Osaka University Graduate School of Medicine, 2\u20132 Yamada-oka, Suita City, Osaka University, Osaka, 565\u20130871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Allergy &amp; Rheumatic Diseases, Osaka University Graduate School of Medicine, 2\u20132 Yamada-oka, Suita City, Osaka University, Osaka, 565\u20130871, Japan"},{"name":"Department of Clinical Application of Biologics, Osaka University Graduate School of Medicine, Osaka University, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,4,8]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1004965"},{"key":"e_1_3_2_3_1","first-page":"946048","article-title":"Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions","author":"Ogata A","year":"2012","unstructured":"Ogata A Tanaka T . Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. Int. J. Rheumatol.2012, 946048 (2012).","journal-title":"Int. J. Rheumatol."},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.4137\/CMAMD.S7371"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2014.01.009"},{"issue":"4","key":"e_1_3_2_6_1","first-page":"851","article-title":"Reshaping a human antibody to inhibit the interleukin-6 dependent tumor cell growth","volume":"53","author":"Sato K","year":"1993","unstructured":"Sato K Tsuchiya M Saldanha J et al. Reshaping a human antibody to inhibit the interleukin-6 dependent tumor cell growth. Cancer Res.53 (4), 851\u2013856 (1993).","journal-title":"Cancer Res."},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204573"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12114"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201040391"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.13.47"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24126"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34477"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-1984-x"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj2650621"},{"key":"e_1_3_2_15_1","first-page":"S4","article-title":"Targeting of interleukin-6 for the treatment of rheumatoid arthritis: a review and update","author":"Tanaka T","year":"2013","unstructured":"Tanaka T Ogata A Kishimoto T . Targeting of interleukin-6 for the treatment of rheumatoid arthritis: a review and update. Rheumatol. Curr. Res.S4 (2013). http:\/\/omicsonline.org\/targeting-of-interleukin-6-for-the-treatment-of-rheumatoid-arthritis-review-and-update-2161-1149.S4-002.php?aid=18750.","journal-title":"Rheumatol. Curr. Res."},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/34.4.321"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650110113"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken363"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11143"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.22.13625"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2010.03.017"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830181122"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310614"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/09629359890875"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.4.461"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199812)41:12<2117::AID-ART6>3.0.CO;2-P"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199908)42:8<1635::AID-ANR11>3.0.CO;2-Q"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.3.1459"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1089\/dna.1992.11.587"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1991.tb04978.x"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.9.1202"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203559"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2011.06.011"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/713618"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22033"},{"key":"e_1_3_2_36_1","first-page":"111","volume-title":"Interleukin-6: Genetics, Clinical Applications and Role in Disease","author":"Ogata A","year":"2013","unstructured":"Ogata A Yoshida Y Morishima A Kumanogoh A Tanaka T . IL-6 Targeting strategy for rheumatoid arthritis. In : Interleukin-6: Genetics, Clinical Applications and Role in Disease. D'AquinoJDeVitoEN (Eds). Nova Science Publishers, Inc, NY, USA, 111\u2013150 (2013)."},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.068064"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-008-0125-1"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.105197"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23940"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60453-5"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092932"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30158"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-012-1108-3"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201282"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204761"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-eular.245"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-eular.2439"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2309-0"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15640-7"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21519"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60250-0"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2012.762037"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2013.854079"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121427"},{"issue":"3","key":"e_1_3_2_56_1","first-page":"63","article-title":"Clinical and radiographic outcomes at two years and the effect of tocilizumab (TCZ) discontinuation following sustained remission in the second year of the ACT-RAY study","volume":"72","author":"Dougados M","year":"2013","unstructured":"Dougados M Donka T Conaghan PG et al. Clinical and radiographic outcomes at two years and the effect of tocilizumab (TCZ) discontinuation following sustained remission in the second year of the ACT-RAY study. Ann. Rheum. Dis.72 (Suppl. 3), 63 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_2_57_1","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"2","author":"Singh JA","year":"2011","unstructured":"Singh JA Wells GA Christensen R et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst. Rev.2, CD008794 (2011).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-008-0111-7"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2011.554810"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12359"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken384"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-009-0243-4"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu172"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1827-x"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jri.2012.05.004"},{"issue":"10","key":"e_1_3_2_66_1","first-page":"S161","article-title":"First experiences with pregnancies in RA patients (pts) receiving tocilizumab (TCZ) therapy","volume":"62","author":"Rubbert-Roth A","year":"2010","unstructured":"Rubbert-Roth A Goupille PM Moosavi S Hou A . First experiences with pregnancies in RA patients (pts) receiving tocilizumab (TCZ) therapy. Arthritis Rheum.62 (10 Suppl.), S161 (2010).","journal-title":"Arthritis Rheum."},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080930"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu035"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.04.031"},{"issue":"3","key":"e_1_3_2_70_1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/annrheumdis-2012-eular.2594","article-title":"Risk factors for major adverse cardiovascular (CV) events (MACE) in rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ)","volume":"71","author":"Rao VU","year":"2012","unstructured":"Rao VU Pavlov A Klearman M et al. Risk factors for major adverse cardiovascular (CV) events (MACE) in rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ). Ann. Rheum. Dis.71 (Suppl. 3), 356 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204345"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61931-4"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.185"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22110"},{"issue":"10","key":"e_1_3_2_75_1","first-page":"S555","article-title":"Effectiveness and tolerability of subcutaneous tocilizumab in rheumatoid arthritis patients switched from intravenous tocilizumab: results from the extension period of the MUSASHI study","volume":"64","author":"Ogata A","year":"2012","unstructured":"Ogata A . Effectiveness and tolerability of subcutaneous tocilizumab in rheumatoid arthritis patients switched from intravenous tocilizumab: results from the extension period of the MUSASHI study. Arthritis Rheum.64 (Suppl. 10), S555 (2012).","journal-title":"Arthritis Rheum."},{"issue":"10","key":"e_1_3_2_76_1","first-page":"S605","article-title":"Safety and efficacy of subcutaneous tocilizumab monotherapy in a long-term extension study in Japanese rheumatoid arthritis patients","volume":"65","author":"Ogata A","year":"2013","unstructured":"Ogata A . Safety and efficacy of subcutaneous tocilizumab monotherapy in a long-term extension study in Japanese rheumatoid arthritis patients. Arthritis Rheum.65 (Suppl. 10), S605\u2013S606 (2013).","journal-title":"Arthritis Rheum."},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP201819"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP201847"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP201904"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203523"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-eular.1831"},{"issue":"10","key":"e_1_3_2_82_1","first-page":"S203","article-title":"The efficacy and safety of tocilizumab subcutaneous versus tocilizumab intravenous, in combination with traditional DMARDs in patients with RA at 49 weeks (SUMMACTA)","volume":"65","author":"Burmester GR","year":"2013","unstructured":"The efficacy and safety of tocilizumab subcutaneous versus tocilizumab intravenous, in combination with traditional DMARDs in patients with RA at 49 weeks (SUMMACTA). BurmesterGRRubbert-RothACantagrelAG. Arthritis Rheum.65 (Suppl. 10), S203\u2013S204 (2013).","journal-title":"Arthritis Rheum."},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-eular.1347"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22384"},{"issue":"10","key":"e_1_3_2_85_1","first-page":"S604","article-title":"The safety and efficacy of tocilizumab subcutaneous in combination with traditional DMARDs in patients with moderate to severe rheumatoid arthritis up to 48 weeks (BREVACTA)","volume":"65","author":"Kivitz A","year":"2013","unstructured":"Kivitz A Olech E Borofsky MA et al. The safety and efficacy of tocilizumab subcutaneous in combination with traditional DMARDs in patients with moderate to severe rheumatoid arthritis up to 48 weeks (BREVACTA). Arthritis Rheum.65 (Suppl. 10), S604\u2013S605 (2013).","journal-title":"Arthritis Rheum."},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket260"}],"container-title":["Therapeutic Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/tde.14.118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:31:05Z","timestamp":1747873865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/tde.14.118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.4155\/tde.14.118"],"URL":"https:\/\/doi.org\/10.4155\/tde.14.118","relation":{},"ISSN":["2041-5990","2041-6008"],"issn-type":[{"value":"2041-5990","type":"print"},{"value":"2041-6008","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=itde20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=itde20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-04-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}